LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.41 3.02

Buy Sell

Overview

Share price change

24h

Current

Min

3.22

Max

3.44

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+358.98% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-66M 188M
Previous open	0.39
Previous close	3.41

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lut 2026, 22:31 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 lut 2026, 22:18 UTC

Earnings

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 lut 2026, 22:11 UTC

Earnings

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 lut 2026, 21:52 UTC

Earnings

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 lut 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 lut 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 lut 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 lut 2026, 23:34 UTC

Market Talk

Earnings

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 lut 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 lut 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 lut 2026, 22:45 UTC

Earnings

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 lut 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 lut 2026, 22:37 UTC

Earnings

Nutrien 4Q EPS $1.18 >NTR.T

18 lut 2026, 22:37 UTC

Earnings

Nutrien 4Q Sales $5.34B >NTR.T

18 lut 2026, 22:35 UTC

Earnings

Pan American Silver 4Q EPS $1.07 >PAAS

18 lut 2026, 22:35 UTC

Earnings

Pan American Silver 4Q Rev $1.18B >PAAS

18 lut 2026, 22:30 UTC

Earnings

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 lut 2026, 22:29 UTC

Earnings

Kinross Gold 4Q EPS 75c >K.T

18 lut 2026, 22:22 UTC

Earnings

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 lut 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 lut 2026, 22:16 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 lut 2026, 22:05 UTC

Earnings

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 lut 2026, 22:03 UTC

Earnings

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Sales $929M >KALU

18 lut 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 lut 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Adj EPS 67c >KGC

18 lut 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Sales $2.02B >KGC

18 lut 2026, 21:56 UTC

Earnings

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 lut 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

358.98% upside

12 Months Forecast

Average 15.33 USD 358.98%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.